/ Media

Product Information

Genentech has multiple products on the market for serious or life-threatening medical conditions. In March 2009, Genentech became a member of the Roche Group, and Genentech now serves as the headquarters for all Roche pharmaceutical operations in the United States.

• Avastin® (bevacizumab) in Metastatic Colorectal Cancer
• Avastin® (bevacizumab) Plus Interferon Alfa In First-Line Metastatic Kidney Cancer
• Avastin Proposed Mechanism of Action
• Avastin® (bevacizumab) in Lung Cancer
• Erivedge® (vismodegib) Capsule in Advanced Basal Cell Carcinoma
• Erivedge® (vismodegib) Development Timeline
• Herceptin® (trastuzumab) in Early-Stage and Advanced Breast Cancer
• Herceptin® (trastuzumab) Development Timeline
• Herceptin® (Trastuzumab) Plus Chemotherapy in HER2-positive Metastatic Stomach (Gastric) Cancer
• Herceptin Proposed Mechanism of Action
• HER2 Testing
• Lucentis® (ranibizumab injection)
• Kadcyla™ (ado-trastuzumab emtansine) Proposed Mechanism of Action
• Pegasys® (peginterferon alfa-2a) in Hepatitis C
• Perjeta® (pertuzumab) in HER2-Positive Metastatic Breast Cancer
• Rituxan® (rituximab) In Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
• Rituxan® (rituximab) Development Timeline
• Rituxan Proposed Mechanism of Action
• Rituxan® (rituximab) in Rheumatoid Arthritis (RA)
• Xolair® (omalizumab) for Subcutaneous Use
• Zelboraf® (vemurafenib) in Metastatic Melanoma
• Roles of the HER2 Family Medicines
• Tarceva (erlotinib) in Non-Small Cell Lung Cancer